| Name | Title | Contact Details |
|---|
SetPoint Medical is developing novel neuromodulation therapies to treat those who suffer from inflammatory diseases such as Crohn`s Disease and rheumatoid arthritis. The company is developing a proprietary and innovative neuromodulation therapy delivery platform consisting of a micro-regulator programmed via a unique prescription pad based interface. This novel therapy will provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payors less than 50% of what today`s leading biologic therapies cost.
For over 35 years, Davis Vision, an award-winning specialty Vision Health Plan, has provided custom designed vision and eyecare programs to corporations, union trust funds and managed care organizations across the country.
Wellpath is the premier provider of localized, high-quality, compassionate care to vulnerable patients in challenging clinical environments. Wellpath holds patients at the center of everything we do and promotes rigorous standards of care and innovation. With nearly 15,000 clinicians and professionals in 35 states across the U.S. and Australia, Wellpath provides medical and mental healthcare services for over 240,000 patients daily in state hospitals, forensic treatment, civil commitment centers, community care centers as well as local, state and federal correctional facilities.
NAVEOS® is the proven leader in maximizing the value of governmental program reimbursements for healthcare providers. Since 2005, our superior approach to data analytics has enabled healthcare providers to realize almost one billion dollars in additional DSH/340B reimbursement payments. NAVEOS® has developed a fully integrated DSH/340B software solution with a national eligibility verification network for both Medicare and Medicaid data. This system, which is the most robust in the industry, uses sophisticated algorithms to match eligibility data with patient data, applies the most up to date Federal and State regulatory parameters, then builds comprehensive deliverables for supporting DSH/340B filings. By leveraging our state-of-the-art technology and unsurpassed domain expertise, we generate best-in-class deliverables that yield impressive value and achieve a stellar (99.7%) audit acceptance rate.
Incapital was founded in 1999 with the mission of providing securities firms and individual investors more efficient access to corporate bonds. While Incapital`s expertise in underwriting and distributing investment-grade corporate bonds remains a core competency, the firm now originates and distributes offerings across multiple asset classes. In addition to its broker-dealer and bank partners, Incapital now serves institutional investors and wealth managers. With over 150 employees in multiple offices in North America, the firm represents over 400 issuing entities and serves 800+ distribution partners. Incapital continues to provide market leadership with a growing range of product offerings, strong strategic partnerships and innovative technology.